Aprecia and Cycle will develop 3D printed orphan drugs
Life-saving drugs for rare disease patients
Aprecia Pharmaceuticals and Cycle Pharmaceuticals will collaborate to develop commercialize orphan drugs manufactured using 3D printing technology.
Both companies are pharmaceutical industries. Aprecia is a 3D printing pharmaceutical company which makes use of ZipDose® Technology, 3D printing technology to create rapidly disintegrating oral dosage forms that are easy to take and easy to administer.
As for Cycle, the company lays emphasis on the optimization of access to existing pharmaceuticals products.
3D printed orphan drugs
The name is quite significant, an orphan drug aims at treating diseases so rare that pharmaceutical industries are reluctant to develop them under usual marketing conditions.
Unlike approved orphan drugs, these drugs will be manufactured using Aprecia’s 3DP ZipDose®Technology platform which is until today the only one approved by the U.S. Food and Drug Administration (FDA).
Antonio Benedetti, CEO of Cycle explains that this technology can formulate “fast-melt pharmaceutical products, incorporating significantly higher amounts of active pharmaceutical ingredient than any other fast-melt technology on the market.” The greatest advantage of this technology is that it can overcome both pill burden and dysphagia – swallowing difficulties, main issues for so many rare disease patients.
As for Don Wetherhold, CEO of Aprecia, he lays emphasis on the common goal of both partners: “deliver quality-of-life improvements to rare disease patients around the world.” As far as the strengths brought by each partner are concerned, he says: “Cycle specializes in orphan drugs – they have proven that they can deliver quality-of-life improvements to rare disease patients around the world. Aprecia is fully committed to applying its ZipDose® 3DP printing technology to address real-world, daily issues faced by rare disease patients.”
For further information about 3D Printing, follow us on our social networks and subscribe to our newsletter!